Melhores Trombocitopenia médicos em Israel - TOP-13 médicos

Custo da consulta disponível mediante solicitação.

• Os detalhes do médico e a especialização estão sendo confirmados.
• Informações adicionais sobre credenciais e experiência estão sendo compiladas.
• Por favor, volte em breve para ver um perfil mais detalhado.

A Dra. El Hasid realizou mais de 300 transplantes de medula óssea e sangue do cordão umbilical no Dana Dwek Children's Hospital. Ela chefia o departamento de Onco-hematologia e Oncologia Pediátrica no local.

• Especializar-se em transplante de medula óssea e sangue do cordão umbilical especificamente para crianças
• Formar-se no prestigiado City of Hope Hospital em Los Angeles
• Autora de mais de 50 publicações científicas e 40 relatórios de conferências
• Membro da American Association for Hematology e da Israeli Society for Pediatric Hematooncology

O Dr. Ram realizou centenas de transplantes de células-tronco para distúrbios sanguíneos, como a trombocitopenia, no Sourasky Medical Center (Ichilov). Ele possui tripla certificação em Medicina Interna, Hematologia e Oncologia Médica.

• Especialização em Hematologia e Oncologia no New York Medical College
• Publicar mais de 30 artigos científicos sobre doenças do sangue e oncologia
• Redigir um capítulo em um livro médico
• Concluir a residência na State University of New York em Brooklyn

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Especialização em Transplante de Medula Óssea – O Dr. Shapira traz vasta experiência no manejo de casos de Trombocitopenia.

• Graduar-se na Faculdade de Medicina da Universidade Hebraica em 1999
• Especializar-se em medicina interna no Hadassah Medical Center
• Médico sênior em Transplante de Medula Óssea no Hadassah
• Falar inglês e hebraico

O Dr. Fredi Aviv tem 31 anos de experiência em onco-hematologia no Sourasky Medical Center.

• Especializar-se no diagnóstico e tratamento de distúrbios sanguíneos
• Longa experiência num centro médico líder em Israel
• Dedicar-se à prestação de cuidados personalizados para condições hematológicas complexas

O Dr. Dror Levin chefia o departamento de hemato-oncologia pediátrica no Sourasky Medical Center, especializando-se em distúrbios sanguíneos pediátricos.

• Diretor de hemato-oncologia pediátrica no Sourasky Medical Center
• Especialista no tratamento de distúrbios de coagulação sanguínea em crianças
• Especializado em hematologia e oncologia pediátrica no Schneider Children's Medical Center
• Membro da ISPHO – Associação israelense de hemato-oncologia pediátrica
• Estudos em oncologia óssea e de tecidos moles no Rizzoli Orthopaedic Institute na Itália

O Dr. Kirshner contribui ativamente para o avanço da hematologia por meio de ensaios clínicos, incluindo um ensaio de fase III para câncer de próstata resistente à castração.

• Realizar especialização clínica em hematologia no Montefiore Medical Center
• Especializar-se em abordagens de tratamento focadas em pesquisa
• Possuir ampla experiência em medicina interna e oncologia

O Dr. Gal Goldstein é um especialista em hemato-oncologia pediátrica no Hadassah Medical Center, listado pela Forbes e reconhecido como um dos melhores médicos de Israel.

• Chefe de Oncologia e Hemato-Oncologia Pediátrica no Hospital Hadassah Ein Kerem
• Especializado em hemato-oncologia pediátrica há mais de 20 anos
• Especialista em retinoblastoma e medicina de precisão
• Membro de múltiplas associações internacionais de oncologia pediátrica
• Realizar transplantes haploidentitários de medula óssea

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.